Is Egrifta (Tesamorelin) Legal in Oregon?

Federal Legal Status of Tesamorelin

Tesamorelin is a Food and Drug Administration-approved prescription medication. The FDA cleared Egrifta (tesamorelin 2 mg) in November 2010 specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [1]. A reformulated version, Egrifta SV (2 mg/mL), received supplemental approval in 2019 [2]. Because tesamorelin has an approved New Drug Application (NDA), it is a legal Schedule-unscheduled (non-controlled) prescription drug under federal law.

The Controlled Substances Act and Tesamorelin

Tesamorelin does not appear on any schedule of the Controlled Substances Act (CSA) [3]. That means prescribers do not need a DEA controlled-substance registration to prescribe it, and pharmacies do not need Schedule-specific storage protocols. Patients may possess it legally with a valid prescription from a licensed provider.

FDA-Approved Indication vs. Off-Label Use

The FDA's approved indication is narrow: reduction of excess visceral abdominal fat in HIV-positive adults [1]. Prescribers in Oregon and elsewhere may legally prescribe tesamorelin off-label for other purposes, such as adult growth hormone deficiency or body-composition optimization, under the medical practice doctrine, which grants physicians wide latitude to use approved drugs for unapproved purposes [4]. The FDA itself states that "once a drug has been approved for sale, a physician may prescribe it for uses or in treatment regimens or patient populations that are not included in approved labeling" [4].

Oregon State Legal Framework

Oregon does not have a state-level statute that separately bans or restricts tesamorelin beyond standard prescription-drug rules. The relevant Oregon legal pillars are the Oregon Board of Pharmacy (OBP), the Oregon Medical Board (OMB), and the Oregon Nurse Practitioner/PA licensing boards.

Oregon Board of Pharmacy Rules

Under Oregon Revised Statutes Chapter 689, all legend (prescription-only) drugs must be dispensed pursuant to a valid prescription from an authorized prescriber [5]. Tesamorelin, as an FDA-approved prescription drug, falls squarely within this system. Oregon pharmacies that stock Egrifta must comply with standard drug storage, labeling, and dispensing regulations. No Oregon Administrative Rule specifically restricts tesamorelin beyond these baseline requirements.

Oregon Medical Board and Prescribing Authority

Oregon-licensed physicians (MDs and DOs), nurse practitioners with prescriptive authority, and physician assistants may all prescribe tesamorelin [6]. The Oregon Medical Board's standard of care framework requires that any prescription, including off-label use, be supported by a legitimate clinical relationship, documented medical history, a diagnosis or reasonable clinical indication, and ongoing monitoring [6]. Prescribing tesamorelin to a patient who has no plausible clinical indication and no documented evaluation could expose a provider to licensure risk under ORS 677.190.

Telehealth Prescribing in Oregon

Oregon's telehealth parity statute (ORS 743A.058) requires commercial insurers to cover telehealth services on par with in-person visits [7]. A clinician may establish a patient-provider relationship via synchronous video and then issue a tesamorelin prescription, provided the encounter meets the Oregon Medical Board's standards for a legitimate clinical evaluation. Because tesamorelin is not a controlled substance, the Ryan Haight Act's in-person examination requirement does not apply, making telehealth prescribing legally straightforward.

Compounded Tesamorelin: A More Complex Picture

Brand-name Egrifta is commercially available and FDA-approved. Compounded tesamorelin is a separate category with its own regulatory hurdles, and the legal picture here is more nuanced.

FDA Bulk Substances List and 503A Pharmacies

Under Section 503A of the Food, Drug, and Cosmetic Act, a traditional compounding pharmacy may prepare drugs for individual patients using bulk active pharmaceutical ingredients (APIs), but only if those APIs are on the FDA's "503A bulks list" or have been nominated and evaluated [8]. Tesamorelin is NOT currently on the FDA's published 503A bulks list of permitted substances [8]. That creates a legal gray zone: a 503A pharmacy compounding tesamorelin for an individual patient is not automatically permitted under the FDA's framework, and the FDA could take enforcement action against such a pharmacy.

503B Outsourcing Facilities

Section 503B outsourcing facilities may compound drugs in larger quantities without patient-specific prescriptions, but they face similar restrictions: bulk substances must appear on the 503B bulks list or be components of an FDA-approved drug [9]. Because tesamorelin has an approved brand-name product, the compounding rationale is harder to justify under the "essentially a copy" prohibition, which bars 503B facilities from producing copies of commercially available drugs unless there is a documented shortage [9]. The FDA maintains a current drug shortage database, and tesamorelin has not appeared on that list in recent years [10].

Oregon-Specific Compounding Rules

Oregon's compounding regulations (OAR 855-019) mirror the federal 503A and 503B framework, incorporating FDA guidance by reference [11]. An Oregon-licensed compounding pharmacy that produces tesamorelin without satisfying federal bulk-substance requirements would be operating outside both federal and state law. Patients receiving compounded tesamorelin from an Oregon pharmacy should ask whether the pharmacy is registered as a 503B outsourcing facility and whether the product's API is sourced from an FDA-registered facility.

The HealthRX clinical team uses a three-checkpoint framework before authorizing any tesamorelin prescription through the platform: (1) confirm FDA-approved brand availability and insurance coverage first, (2) if compounding is considered, verify the pharmacy holds 503B registration and the API supplier is FDA-registered, and (3) document the clinical indication with objective measures (DXA or CT for visceral fat, IGF-1 level, HIV treatment history if applicable) before the first prescription is issued.

How to Get Egrifta (Tesamorelin) in Oregon

Patients in Oregon have several pathways to obtain a legal tesamorelin prescription.

Step 1: Establish a Clinical Relationship

A prescriber must evaluate the patient before writing the prescription. For the on-label HIV-lipodystrophy indication, documentation of HIV-positive status, current antiretroviral therapy, and excess visceral fat measured by waist circumference or imaging is required per the Egrifta prescribing information [12]. For off-label use, the prescriber should document their clinical reasoning.

Step 2: Choose a Prescriber Type

Any Oregon-licensed MD, DO, NP (with prescriptive authority), or PA may prescribe tesamorelin. Endocrinologists, infectious disease specialists, and anti-aging or hormone-therapy clinics are the most common prescriber types. Telehealth platforms licensed in Oregon may also initiate prescriptions after a qualifying synchronous visit.

Step 3: Fill the Prescription

Brand-name Egrifta can be dispensed through specialty pharmacies. Theratechnologies operates a patient-support program called Egrifta Support that assists with prior authorization and access [12]. Retail pharmacies may stock it or order it; call ahead to confirm. Insurance coverage for the on-label indication (HIV lipodystrophy) is generally available under commercial plans and Oregon Health Plan (Medicaid) formularies, though prior authorization is often required.

Step 4: Ongoing Monitoring

The Egrifta prescribing information specifies reassessment at 6 months using waist circumference or imaging. Glucose metabolism should be monitored, as tesamorelin can increase insulin resistance; one phase 3 trial (N=543) found a statistically significant increase in HbA1c of 0.12% relative to placebo at 26 weeks [13]. Patients with pre-existing diabetes require closer glycemic surveillance.

Clinical Evidence Supporting Tesamorelin Use

Understanding the evidence base helps clinicians justify prescribing and helps patients understand what to expect.

Phase 3 Trial Data for HIV Lipodystrophy

The key trials that supported FDA approval enrolled HIV-positive adults on stable antiretroviral therapy. In a pooled analysis of two phase 3 trials (combined N=816), tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by a mean of 15.2% from baseline versus a 4.8% reduction in the placebo group at 26 weeks (P<0.0001) [13]. Trunk fat ratio and patient-reported body-image scores also improved significantly. These results were published in The Lancet HIV's predecessor journal and cited in the FDA approval package [13].

IGF-1 and Growth Hormone Axis Effects

Tesamorelin acts as a growth hormone-releasing hormone (GHRH) analogue, stimulating pituitary release of endogenous growth hormone and subsequently raising IGF-1. In trial data, IGF-1 levels increased by approximately 78 mcg/L from baseline in the tesamorelin group versus a decrease of 3 mcg/L in the placebo group [13]. Clinicians should measure baseline IGF-1 and monitor levels during treatment; a supranormal IGF-1 (above the age-adjusted reference range) is grounds for dose reduction or temporary discontinuation per the prescribing information [12].

Cardiovascular and Metabolic Markers

A secondary analysis of trial data found that tesamorelin produced a 15% reduction in triglycerides and a non-significant trend toward reduced LDL-C at 26 weeks in the HIV-lipodystrophy population [14]. The clinical significance of these lipid changes for cardiovascular risk reduction has not been established in an outcomes trial. Clinicians should not represent tesamorelin as a proven cardiovascular risk reducer until such data exist.

Safety Profile

Common adverse events in phase 3 trials included injection-site reactions (9.6% tesamorelin vs. 4.3% placebo), arthralgias (7.6% vs. 4.0%), and peripheral edema (5.0% vs. 1.9%) [13]. The FDA label carries a contraindication for active malignancy, active disruption of the hypothalamic-pituitary axis (such as pituitary tumor or cranial irradiation), and pregnancy [12]. Oregon prescribers should screen for these contraindications at baseline.

Insurance Coverage and Cost in Oregon

Brand-name Egrifta can cost between $3,000 and $7,000 per month at list price without insurance. Oregon Medicaid (Oregon Health Plan) covers Egrifta for the FDA-approved HIV-lipodystrophy indication with prior authorization [15]. Commercial insurers operating in Oregon are subject to the state's Affordable Care Act exchange rules, and most major carriers include tesamorelin on specialty tier formularies for the on-label use.

For off-label prescriptions, insurance coverage is far less predictable. Some carriers will deny off-label tesamorelin outright; others may cover it with a letter of medical necessity. Theratechnologies offers a co-pay assistance program for commercially insured patients, which can reduce out-of-pocket costs significantly [12].

Risks of Obtaining Tesamorelin Without a Prescription

Purchasing tesamorelin from unregulated online vendors without a prescription is illegal under federal law and Oregon ORS 689.527, which prohibits obtaining prescription drugs without a valid prescription [5]. Beyond the legal risk, unregulated peptide products sold as "research chemicals" may contain incorrect doses, microbial contamination, or entirely different compounds. The FDA has issued multiple warning letters to vendors selling unapproved injectable peptides [16]. A 2023 FDA laboratory analysis found that a sample of "tesamorelin" purchased from a research-chemical vendor contained less than 60% of the labeled peptide content and detectable endotoxin levels [16].

Summary Table: Tesamorelin Legal Pathways in Oregon

| Pathway | Legal Status | Key Requirement | |---|---|---| | Brand Egrifta, on-label (HIV-HAL) | Fully legal | Valid prescription, licensed Oregon pharmacy | | Brand Egrifta, off-label | Legal (prescriber's discretion) | Documented clinical indication | | 503B compounded tesamorelin | Conditionally permitted | 503B facility registration, no active brand shortage exception | | 503A compounded tesamorelin | Restricted / gray area | Not on FDA 503A bulks list; enforcement risk | | No-prescription "research chemical" | Illegal | N/A |